比较强化剂量密集表柔比星、紫杉醇、环磷酰胺与每周紫杉醇、脂质体多柔比星(三阴性乳腺癌加卡铂)新辅助化疗的高危早期乳腺癌随机III期GeparOcto试验的生存分析
GeparOcto试验随机比较高危早期乳腺癌患者接受iddEPC方案或PM(Cb)方案新辅助化疗,中位随访47.0个月,全队列4年iDFS和OS无显著差异,但HR+/HER2-亚组接受iddEPC的4年iDFS和OS显著更优。
要点
- 全队列4年iDFS iddEPC组81.9% vs PM(Cb)组79.7%,HR=1.16,无显著差异。
- 全队列4年OS iddEPC组90.3% vs PM(Cb)组90.6%,HR=0.90,无显著差异。
- HR+/HER2-亚组4年iDFS iddEPC组77.9% vs PM组62.5%,HR=2.11,显著优于PM。
核心结论
- 全队列生存无差异,但HR+/HER2-亚组显著受益于iddEPC,支持NACT超越pCR的额外效应概念。
研究设计与样本
- 随机III期GeparOcto试验,945例患者开始治疗(iddEPC组470例,PM(Cb)组475例),中位随访47.0个月(范围1.6-61.5个月)。
主要发现
- 报告162例iDFS事件(iddEPC组75例,PM(Cb)组87例)和79例死亡(iddEPC组41例,PM(Cb)组38例)。
- 全队列4年iDFS:iddEPC组81.9% vs PM(Cb)组79.7%,HR=1.16(95%CI 0.85-1.59),log-rank p=0.334,无显著差异。
- 全队列4年OS:iddEPC组90.3% vs PM(Cb)组90.6%,HR=0.90(95%CI 0.58-1.40),log-rank p=0.637,无显著差异。
- HER2+和TNBC亚组中iDFS和OS均无显著差异。
- HR+/HER2-亚组4年iDFS:iddEPC组77.9% vs PM组62.5%,HR=2.11(95%CI 1.08-4.10),log-rank p=0.025,iddEPC显著更优。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: GeparOcto demonstrated that pathological complete response (pCR) of intense dose-dense epirubicin, paclitaxel and cyclophosphamide (iddEPC) was comparable to weekly paclitaxel/non-pegylated liposomal doxorubicin (plus carboplatin (PM(Cb) in triple-negative breast cancer [TNBC]) in high-risk early breast cancer (BC). Here, we report time-to-event secondary end-points. PATIENTS AND METHODS: Patients were randomised to receive 18 weeks of E (150 mg/m2) followed by P (225 mg/m2) followed by C (2000 mg/m2), each q2w or weekly P (80 mg/m2) plus M (20 mg/m2) plus, in TNBC, Cb (AUC 1.5). Patients with human epidermal growth factor receptor 2-positive (HER2+)BC received trastuzumab (6[loading dose 8]mg/kg q3w) and pertuzumab (420[840]mg q3w) with P and C cycles. RESULTS: 945 patients started treatment (iddEPC n = 470; PM(Cb) n = 475). After a median follow-up of 47.0 (range 1.6-61.5) months, 162 (75 in iddEPC; 87 in PM(Cb)) invasive disease-free survival (iDFS) events and 79 (41 in iddEPC; 38 in PM(Cb)) deaths were reported. No significant difference was observed in 4-year iDFS (81.9% iddEPC versus 79.7% PM(Cb), HR = 1.16 [95%CI 0.85-1.59], log-rank p = 0.334) or 4-year overall survival (OS) (90.3% iddEPC versus 90.6% PM(Cb), HR = 0.90 [95%CI 0.58-1.40], log-rank p = 0.637) overall and in HER2+ and TNBC subgroups. HR+/HER2- BC patients, however, had significantly better 4-year iDFS (77.9% iddEPC versus 62.5% PM, HR = 2.11 [95%CI 1.08-4.10], log-rank p = 0.025) and 4-year OS with iddEPC (94.7% iddEPC versus 80.1% PM, HR = 3.26 [95%CI 1.06-10.00], log-rank p = 0.029). CONCLUSION: While there was no difference in survival for the entire cohort, the HR+/HER2-subgroup significantly benefits from iddEPC. This supports the concept of an additional effect of NACT beyond pCR in patients with HR+/HER2- BC. CLINICALTRIALS. GOV IDENTIFIER: NCT02125344.
引用
- Schneeweiss A, Michel LL, Möbus V, et al. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer. 2021. PMID: 34801353. doi:10.1016/j.ejca.2021.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。